Renal Cell Carcinoma

Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.

According to findings from the phase III ATLAS trial, disease-free survival was not extended with adjuvant axitinib (Inlyta) versus placebo for patients at high risk of recurrent renal cell carcinoma after nephrectomy.

Ani S. Balmanoukian, MD, discusses immunotherapy developments in GU malignancies

Treatment of renal cell carcinoma (RCC) is awaiting the potential integration of combinations of immuno-oncology agents like nivolumab (Opdivo) and ipilimumab (Yervoy), or combinations of targeted therapies with checkpoint inhibitors into the treatment paradigm. In an interview with&nbsp;<em>Targeted Oncology</em>, Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Hans Hammers, MD, PhD, associate professor at the University of Texas Southwestern Medical Center, discusses what he believes is most important in future investigation for the treatment of patients with renal cell carcinoma. With combination therapies on the rise in the field of kidney cancers, new pivotal and early clinical trials are constantly arising looking at new combination regimens.

Kidney Cancer

Lung Cancer

Newer combination regimens are about to make their way into the treatment paradigm in RCC, with promising data fueling excitement for these approaching regimens.&nbsp;Each of the combinations approaching addition to the treatment paradigm for patients with RCC incorporates immunotherapy, demonstrating the growing role of this modality.

Lenvatinib mesylate, an oral tyrosine kinase inhibitor, will continue to be developed and commercialized worldwide by its creator, Japan&rsquo;s Eisai Co. Ltd, in a strategic collaboration with Merck, which is better known as MSD outside of the United States and Canada. The partnership between the 2 companies was announced on March 7.